Lilly to Acquire Key Genomic Medicine Platforms and Prion Disease Program from Bankrupt Sangamo
LLY sits 78% above its 52-week low of $623.78.
Summary
Eli Lilly has entered an agreement to acquire Sangamo Therapeutics' capsid delivery, zinc finger, and modular integrase (MINT) platforms, along with the ST-506 prion disease program. This acquisition is part of Sangamo's Chapter 11 bankruptcy proceedings, where Lilly will serve as a "stalking horse" bidder. This strategic asset acquisition follows Lilly's recent FDA approval of Foundayo and a $6.3 billion acquisition of Centessa's OX2R agonist assets, indicating continued expansion of its pipeline and technological capabilities. Acquiring these genomic medicine platforms and a specific disease program enhances Lilly's R&D capabilities, potentially at a favorable valuation due to Sangamo's bankruptcy.
At the time of this announcement, LLY was trading at $1,108.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.